Endometrial Transitional Cell Carcinoma
Associated Genetic Biomarkers
NCI Definition: A rare primary carcinoma of the endometrium characterized by the presence of malignant epithelial cells resembling urothelial transitional cells. The malignant transitional cells constitute at least 90% of the tumor cells. 
There are 4 clinical trials for endometrial transitional cell carcinoma, of which 3 are open and 1 is completed or closed. Of the trials that contain endometrial transitional cell carcinoma as an inclusion criterion, 1 is phase 1/phase 2 (0 open) and 3 are phase 2 (3 open).
ER and PR are the most frequent gene inclusion criteria for endometrial transitional cell carcinoma clinical trials .
Abemaciclib, anlotinib, and atezolizumab are the most common interventions in endometrial transitional cell carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.